* Integra Lifesciences Holdings Corp IART.OQ IART.O is
expected to show a fall in quarterly revenue when it reports
results on July 27.
* The Princeton New Jersey-based company is expected to
report a
6.0% decrease in revenue to $374.067 million from $397.82
million a year ago, according to the mean estimate from 10
analysts, based on Refinitiv data. The company's guidance on May
23 2023, for the period ended June 30, was for revenue between
$372.00 million and $376.00 million.
* Refinitiv's mean analyst estimate for Integra
Lifesciences
Holdings Corp is for earnings of 57 cents per share. The
company's EPS guidance on May 23 2023, for the period ended June
30, was between $0.55 and $0.59
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 7
"hold" and 4 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Integra
Lifesciences Holdings Corp is $47, above its last closing
price of $45.69.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Mar. 31 2023 0.74 0.74 0.74 Met 0.4
Dec. 31 2023 0.91 0.90 0.94 Beat 4.1
Sep. 30 2022 0.71 0.72 0.86 Beat 19.5
Jun. 30 2022 0.80 0.80 0.81 Beat 1.6
Mar. 0.68 0.68 0.74 Beat 8.8
31 2022
Dec. 31 2021 0.84 0.83 0.84 Beat 0.7
Sep. 30 2021 0.72 0.72 0.86 Beat 18.7
Jun. 30 2021 0.67 0.66 0.79 Beat 19.9
This summary was machine generated July 25 at 18:33 GMT. All
figures in US dollars unless otherwise stated